Study of Alzheimer′s Disease Biomarkers Based onSerum Peptidomics
10.11895/j.issn.0253-3820.170248
- VernacularTitle:阿尔兹海默症血清多肽组生物标志物研究
- Author:
Xiangyi KONG
;
Jianshi DU
;
Ming MA
;
Jinling XU
;
Shuiming LI
;
Yong WANG
;
Qing ZHAO
- Keywords:
Peptidomics;
Biomarker;
Serum;
Alzheimer′s disease;
Mild cognitive impairment
- From:
Chinese Journal of Analytical Chemistry
2017;45(7):937-943
- CountryChina
- Language:Chinese
-
Abstract:
Early diagnosis and intervention is an important way to delay the progress of Alzheimer′s disease (AD).Compared with cerebrospinal fluid, blood sampling is not invasive and easy to be obtained in clinic practice.In this study, the serum samples of 9 controls, 10 AD and 12 mild cognitive dysfunction (MCI) patients were analyzed and compared through one by one analysis to screen potential markers for AD diagnosis.The experimental results showed that VGFYESDVMGR of α-2-macroglobulin peptide was closely related to the late stage of AD disease, and the large amount degradation of apolipoprotein C-Ⅲ, histone H1.2 and histone H1.4 was significantly related to early stages of AD progression.The characteristics of serum peptidome were different for the early and late AD, and these four proteins may be used as potential biomarkers of AD disease.In addition, the obvious ladder sequence characteristic was observed for apolipoprotein C-Ⅲ and histone H1, which could partly explain why the peptides distribution in different samples was somewhat contingent.On the contrary, the distribution at protein level was more stable.Finally, it was confirmed that the peptides of proteins such as fibrinogen α-chain, thymosin β-4 and patchy proteins were the dominant peptides in all serum samples.Overall, this study showed that the method of using serum peptidomics to diagnose AD was possible.The results may provide evidence and references for the large-scale clinical validation of AD.
